Genmab | GEN - Des Atouts





Des Atouts Changement Date
Agios Pharmaceuticals USD 1.06B 44.38M 2026-09
Almirall EUR 2.37B 29.97M 2026-06
Amarin USD 634.08M 9.72M 2026-09
Amgen USD 96.05B 409M 2026-09
argenx SE USD 10.03B 1.35B 2026-06
AstraZeneca USD 119.92B 4.09B 2026-09
Bayer EUR 113.47B 6.18B 2026-09
BioMarin Pharmaceutical USD 11.57B 154.21M 2026-09
Demant DKK 40.03B 951M 2026-06
Exelixis USD 2.51B 19.26M 2026-09
Fresenius Medical Care EUR 31.45B 155.97M 2026-09
Genmab DKK 12.52B 139M 2026-06
GlaxoSmithKline GBP 71.7B 9.96B 2026-09
GN Store Nord DKK 30.31B 762M 2026-09
GRIFOLS EUR 20.28B 191M 2026-09
Hikma Pharmaceutical USD 5.67B 117M 2025-12
Insmed USD 2.23B 123.49M 2026-09
Lakefront Biotherapeutics EUR 3.35B 21.24M 2026-06
Lonza CHF 18.97B 164M 2025-12
Merck EUR 53.66B 975M 2026-09
Novartis USD 117.15B 4.88B 2026-09
Regeneron Pharmaceuticals USD 44.41B 2.67B 2026-09
Roche Holding CHF 98.2B 2.5B 2026-06
Sanofi EUR 130.29B 1.23B 2026-09
UCB EUR 18.16B 971M 2025-12